An evaluation of risperidone drug interactions

Journal of Clinical Psychopharmacology

Volumn 21, Issue 4, 2001, Pages 408-416

  DeVane, C Lindsay ^a   Nemeroff, Charles B ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BENZODIAZEPINE; BIPERIDEN; CARBAMAZEPINE; CIMETIDINE; CITALOPRAM; CLOMIPRAMINE; CLOZAPINE; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DIAZEPAM; DIGOXIN; DONEPEZIL; FLUOXETINE; LITHIUM; MESORIDAZINE; MIRTAZAPINE; NEUROLEPTIC AGENT; PAROXETINE; PSYCHOTROPIC AGENT; RANITIDINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; UNINDEXED DRUG; VALPROIC ACID;

ALZHEIMER DISEASE; ARTICLE; COMORBIDITY; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG METABOLISM; ENZYME INHIBITION; HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; SCHIZOPHRENIA; TREATMENT OUTCOME;

ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BLOOD PROTEINS; CARDIOVASCULAR AGENTS; CHOLINERGIC ANTAGONISTS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; GASTROINTESTINAL AGENTS; HUMANS; LIVER; PROTEIN BINDING; RISPERIDONE;

EID: 0034913055     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-200108000-00008     Document Type: Article

References (54)

1. Adverse effects of the atypical antipsychotics
2. Copharmacy strategies for bipolar disorder
3. Polypharmacy in the elderly: Clinical implications
4. Risperidone in the treatment of schizophrenia
5. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients
6. Polymorphic cytochromes P450 and drugs used in psychiatry
7. Drugs as substrates of metabolic enzymes: Antipsychotics
8. Absorption, metabolism, and excretion of risperidone in humans
9. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects
10. Stimulation by risperidone of rat prolactin secretion in vivo and in cultured pituitary cells in vitro
11. Principles of pharmacokinetics and pharmacodynamics
12. A pilot study on risperidone metabolism: The role of cytochromes P460 2D6 and 3A
13. Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4
14. Protein binding displacement interactions and their clinical importance
15. Methods of determining plasma and tissue binding of drugs. Pharmacokinetic consequences
16. Plasma protein binding of risperidone and its distribution in the blood
17. The pharmacokinetics of risperidone in humans: A summary
18. No effect of citalopram on plasma levels of clozapine, risperidone and their active metabolites in patients with chronic schizophrenia
19. Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4
20. Therapeutic drug monitoring of risperidone using a new, rapid HPLC method: Reappraisal of interindividual variability factors
21. Lack of effect of amitriptyline on risperidone pharmacokinetics in schizophrenic patients
22. Pharmacokinetics and clinical effects of therapy with fluoxetine plus risperidone in adult patients with psychosis
23. Lack of drug interactions between mirtazapine and risperidone in psychiatric patients: A pilot study
24. Pharmacokinetics and safety of therapy with lithium plus risperidone in adult patients with psychosis
25. Risperidone as an adjunct to clozapine therapy in chronic schizophrenics
26. Risperidone and cytochrome P450 3A
27. Pharmacokinetic interaction between risperidone and clozapine
28. Serum concentrations and side effects in psychiatric patients during risperidone therapy
29. Pharmacokinetics of risperidone/donepezil combination
30. Risperidone may worsen fluoxetine-treated OCD
31. Erythromycin interaction with risperidone or clomipramine in an adolescent
32. Enuresis with combined risperidone and SSRI use
33. Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder
34. Therapeutic effect and safety of adjunctive risperidone in refractory obsessive-compulsive disorder
35. Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders
36. Risperidone addition in serotonin reuptake inhibitor-resistant trichotillomania: Three cases
37. Risperidone addition in fluvoxamine-refractory obsessive-compulsive patients: Three cases
38. Risperidone-induced tardive dyskinesia
39. Delirium induced by lithium and risperidone combination
40. Augmentation of risperidone with valproic acid
41. Drug interaction between risperidone and phenytoin resulting in extrapyramidal symptoms
42. Antidepressant usage in schizophrenia
43. Benzodiazepines in the treatment of schizophrenia: A review and reappraisal
44. The use of benzodiazepines in the treatment of schizophrenia
45. Clinical relevance of cimetidine drug interactions
46. Antipsychotics in bipolar disorder
47. Efficacy of risperidone treatment for psychoses associated with schizophrenia, schizoaffective disorder, bipolar disorder, or senile dementia in 11 geriatric patients: A case study
48. Metabolism, bioavailability, and drug interactions
49. Risperidone in the elderly: A pharmacoepidemiologic study
50. Psychotropic drug interactions: 1999
51. Pharmacokinetics and drug interactions: Update for new antipsychotics
52. Risperidone - A review of its pharmacology and therapeutic potential in the treatment of schizophrenia
53. Debrisoquine hydroxylation phenotyping in geriatric psychopharmacology